Artelo Biosciences, Inc. (ARTL) | Solana Treasury Stock

Artelo Biosciences, Inc.
ARTL
$0.73 (1.55%)
Last update 05:03 PM UTC · Aug 10 · NASDAQ
#22 Solana Treasuries
Artelo Biosciences, Inc.
ARTL
#22 in Solana Treasuries
Solana Treasury Stock · NASDAQ · Solana Beach, US
$0.73 (1.55%)
Last update 05:03 PM UTC · Aug 10, 2026
SOL Holdings
1,525 SOL Treasury
Market Cap
$2.55M
Enterprise Value
-$7.1M

Market Overview

Market Cap
$2,552,112
Shares Outstanding
3,485,540
50-Day Moving Average
$1.12
200-Day Moving Average
$4.02
Average Volume (20 Days)
173,329
Beta (5Y)
-0.07

Price History

Date OPEN HIGH LOW CLOSE VWAP VOLUME %CHG $CHG

Artelo Biosciences, Inc. Company Overview

Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company developing treatments that modulate the endocannabinoid system, with a pipeline including ART27.13 (Phase 1b/2a anorexia-associated-with-cancer), ART12.11 (cocrystal cannabidiol for inflammatory bowel disease and PTSD), and ART26.12 (a fatty-acid-binding-protein-5 inhibitor with peer-reviewed efficacy across visceral, inflammatory, neuropathic, and joint pain models). Artelo recently regained Nasdaq listing compliance and entered an AI-driven research collaboration with ScienceMachine to identify novel FABP5 inhibitor mechanisms. The company holds Solana on its balance sheet.

Artelo Biosciences, Inc. website url Visit Website Artelo Biosciences, Inc. linkedin url Artelo Biosciences, Inc. twitter url
Stock Exchange NASDAQ
IPO Date 2019-06-21
Number of Employees 7
Headquarters Solana Beach, CA, US

Key Executives

Mark E. Spring

Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer
Mark E. Spring linkedin Mark E. Spring twitter

Andrew Yates

Senior Vice President & Chief Scientific Officer
Andrew Yates linkedin Andrew Yates twitter

Steven D. Reich

Chief Medical Officer
Steven D. Reich linkedin Steven D. Reich twitter

Jason H. Baybutt

Senior Vice President of Finance
Jason H. Baybutt linkedin Jason H. Baybutt twitter

Gregory D. Gorgas

President, Chief Executive Officer, Secretary & Director
Gregory D. Gorgas linkedin Gregory D. Gorgas twitter

Featured Posts

View all articles

Press Releases

No press releases found.

SEC Filings

Form Type Filed Accepted Source

ARTL Frequently Asked Questions

The next earnings report date for Artelo Biosciences, Inc. (ARTL) is scheduled for August 12, 2026. Stay up to date with ’s financial results and key announcements by visiting our Earnings Tracker or by subscribing to earnings alerts. Here we also provide ARTL earnings call summaries and transcripts.

As of September 30, 2025, Artelo Biosciences, Inc. holds approximately 1,524.69 SOL . For more comprehensive insights, you can track ARTL 's Solana holdings on our Solana Treasuries page.

The current stock price of Artelo Biosciences, Inc. (ARTL) is $0.73 as of 05:03 PM UTC · Aug 10, 2026 . For live stock updates and company rankings, view our Bitcoin mining stocks by market cap table.

The latest news for Artelo Biosciences, Inc. (ARTL) includes Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma published on August 10, 2026 . For more details and ongoing updates, visit the ARTL news section.